We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
With tax reform in place and corporations expecting lower taxes and easier access to overseas cash, the biopharma industry focus has been on potential merger-and-acquisition activity.